Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
54.07
-2.99 (-5.24%)
At close: May 5, 2025, 4:00 PM
53.04
-1.03 (-1.90%)
Pre-market: May 6, 2025, 7:06 AM EDT
Tempus AI Revenue
In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth. Tempus AI had revenue of $200.68M in the quarter ending December 31, 2024, with 35.85% growth.
Revenue (ttm)
$693.40M
Revenue Growth
+30.38%
P/S Ratio
9.35
Revenue / Employee
$288,916
Employees
2,400
Market Cap
9.36B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
TEM News
- 22 hours ago - Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Business Wire
- 4 days ago - Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment - Business Wire
- 6 days ago - Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection - Business Wire
- 7 days ago - Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - Business Wire
- 10 days ago - Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Business Wire
- 11 days ago - Tempus to Report First Quarter 2025 Financial Results on May 6 - Business Wire
- 12 days ago - Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology - Business Wire
- 14 days ago - Tempus AI: Cooldown Arrived (Rating Upgrade) - Seeking Alpha